FAP-inhibitor radiopharmaceuticals have been designed for PET/CT imaging, demonstrating a favorable biodistribution in normal tissues, a high tumor-to-background ratio, and high efficacy of [68Ga]FAPI PET/CT in staging and restaging tumors eligible for neo-adjuvant treatment and surgery [50,51,52,53]. The gene discussed is FAP; the disease is neoplasm.